Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety
| Status: | Terminated |
|---|---|
| Conditions: | Anxiety |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 50 - 90 |
| Updated: | 4/21/2017 |
| Start Date: | July 2009 |
| End Date: | February 2012 |
The Effect of Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety for Patients Undergoing First Eye Cataract Surgery
Cranial electro stimulation (CES) provides safe, adequate, side-effect free sedation without
excessive drowsiness in preoperative settings.
excessive drowsiness in preoperative settings.
CES Alpha-Stim is a non-invasive device which has been in place and has been approved for
patients to reduce anxiety by the FDA. This study involves the use of CES Alpha-Stim device
applied to the patient 30 minutes before and through-out cataract surgery procedure and then
to measure the level of anxiety and discomfort by using a visual analog scale (VAS). We
propose that by applying the device the patients will be able to have markedly less level of
anxiety and discomfort before and during the surgery and will ultimately avoid the
traditional use of sedative or analgesic drugs being used for these kinds of surgery.
patients to reduce anxiety by the FDA. This study involves the use of CES Alpha-Stim device
applied to the patient 30 minutes before and through-out cataract surgery procedure and then
to measure the level of anxiety and discomfort by using a visual analog scale (VAS). We
propose that by applying the device the patients will be able to have markedly less level of
anxiety and discomfort before and during the surgery and will ultimately avoid the
traditional use of sedative or analgesic drugs being used for these kinds of surgery.
Inclusion Criteria:
- Patients of both genders between 50 and 90 years old scheduled for an outpatient
"first eye" cataract phacoemulsification with topical anesthesia.
- ASA classification I II and III
Exclusion Criteria:
- ASA classification IV (patients with a chronic or severe disease).
- Hypersensitivity to midazolam or benzodiazepines
- acute narrow-angle glaucoma
- untreated open-angle glaucoma
- Patients with any sort of psychiatric or neurological disorder
- Patients on anti-anxiety medication
- Patients who have demand-type pacemakers installed before 1999* *Note: These are the
exclusions listed for liability purposes by Alpha-Stim. There are no FDA exclusions.
We found this trial at
1
site
Click here to add this to my saved trials
